Industries > Pharma > Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027

Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs

PUBLISHED: 14 December 2017
PAGES: 162
PRODUCT CODE: PHA0267
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0267 Categories: ,

The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2016, the anti-fibrotics held the largest market share (52%) followed by the tyrosine kinase inhibitors.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 162-page report you will receive 57 tables and 97 figures– all unavailable elsewhere.

The 162-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market size. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2027

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:
– Antifibrotics
– Tyrosine Kinase Inhibitors
– Anti-inflammatory Drugs
– Immunosuppressants
– Other MoA

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:
– Innovator Drugs
– Off-label Drugs

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
– Japan
– EU5: Germany, France, the UK, Italy, Spain
– Rest of Europe
– Rest of World

• This report provides individual revenue forecasts to 2027 for these marketed drugs:
– Esbriet
– Ofev

• Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:
– Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets (Historical 2010-2015, 2016 data, Forecast 2017-2027)
– Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
– Epidemiology of Idiopathic Pulmonary Fibrosis by gender
– Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
– A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs market

• Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipeline anti-idiopathic pulmonary fibrosis drugs from these companies:
– Actelion
– Afferent Pharmaceuticals
– Asahi Kasei Pharma
– Bellerophon Therapeutics
– Biogen
– Boehringer Ingelheim
– FibroGen
– Galapagos
– Galecto Biotech
– Genentech
– Global Blood Therapeutics
– GSK
– Kadmon Pharmaceuticals
– LTT Bio-Pharma
– MediciNova
– Merck
– Moerae
– Pacific Therapeutics
– Promedior
– ProMetic Life Sciences
– Roche
– Sanofi
– Teva
– Zai Lab

Visiongain’s study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.

Buy our report today Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs, Off-label Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027

    Download sample pages

    Complete the form below to download your free sample pages for Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027

      Latest Pharma news

      Visiongain Publishes Antibiotics Market Report 2023-2033

      The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Clinical Trial Supplies Market Report 2023-2033

      The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2023-2033

      The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.

      31 January 2023

      READ

      Visiongain Publishes Human Microbiome Market Report 2023-2033

      The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.

      30 January 2023

      READ